Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Marinus van Marwijk Kooy"'
Autor:
Ruth Wester, Bronno van der Holt, Emelie Asselbergs, Sonja Zweegman, Marie Jose Kersten, Edo Vellenga, Marinus van Marwijk Kooy, Okke de Weerdt, Monique Minnema, Sarah Lonergan, Antonio Palumbo, Henk Lokhorst, Annemiek Broijl, Pieter Sonneveld
Publikováno v:
Haematologica, Vol 104, Iss 11 (2019)
This is a phase II dose escalation trial of carfilzomib in combination with thalidomide and dexamethasone for induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The results of four dose levels ar
Externí odkaz:
https://doaj.org/article/a2acee6047bf4427b3e655576fd11ec2
Autor:
Jeroen Janssen, Bob Löwenberg, Markus Manz, Mario Bargetzi, Bart Biemond, Peter von dem Borne, Dimitri Breems, Rolf Brouwer, Yves Chalandon, Dries Deeren, Anna Efthymiou, Bjørn-Tore Gjertsen, Carlos Graux, Michael Gregor, Dominik Heim, Urs Hess, Mels Hoogendoorn, Aurelie Jaspers, Asiong Jie, Mojca Jongen-Lavrencic, Saskia Klein, Marjolein van der Klift, Jürgen Kuball, Danielle van Lammeren-Venema, Marie-Cecile Legdeur, Arjan van de Loosdrecht, Johan Maertens, Marinus van Marwijk Kooy, Ine Moors, Marten Nijziel, Florence van Obbergh, Margriet Oosterveld, Thomas Pabst, Marjolein van der Poel, Harm Sinnige, Olivier Spertini, Wim Terpstra, Lidwine Tick, Walter van der Velden, Marie-Christiane Vekemans, Edo Vellenga, Okke de Weerdt, Peter Westerweel, Georg Stüssi, Yvette van Norden, Gert Ossenkoppele
Publikováno v:
Cancers, Vol 13, Iss 4, p 672 (2021)
Treatment results of AML in elderly patients are unsatisfactory. We hypothesized that addition of tosedostat, an aminopeptidase inhibitor, to intensive chemotherapy may improve outcome in this population. After establishing a safe dose in a run-in ph
Externí odkaz:
https://doaj.org/article/24fe32a58d25457ab838d412b4becc0b
Autor:
Wendy Deenik, Jeroen J.W.M. Janssen, Bronno van der Holt, Gregor E.G. Verhoef, Willem M. Smit, Marie José Kersten, Simon M.G.J. Daenen, Leo F. Verdonck, Augustin Ferrant, Anton V.M.B. Schattenberg, Pieter Sonneveld, Marinus van Marwijk Kooy, Shulamit Wittebol, Roelof Willemze, Pierre W. Wijermans, H. Berna Beverloo, Bob Löwenberg, Peter J.M. Valk, Gert J. Ossenkoppele, Jan J. Cornelissen
Publikováno v:
Haematologica, Vol 95, Iss 6 (2010)
Background In order to improve the molecular response rate and prevent resistance to treatment, combination therapy with different dosages of imatinib and cytarabine was studied in newly diagnosed patients with chronic myeloid leukemia in the HOVON-5
Externí odkaz:
https://doaj.org/article/52ff014faa724e5c9930e7aea97fd445
Autor:
Tim Grob, Mathijs A. Sanders, Christian M. Vonk, Franҫois G. Kavelaars, Melissa Rijken, Diana W. Hanekamp, Patrycja L. Gradowska, Jacqueline Cloos, Yngvar Fløisand, Marinus van Marwijk Kooy, Markus G. Manz, Gert J. Ossenkoppele, Lidwine W. Tick, Violaine Havelange, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter J.M. Valk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4):JCO2200715, 756-765. American Society of Clinical Oncology
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 756-765. American Society of Clinical Oncology
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, ' Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765 . https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(4), 756-765. American Society of Clinical Oncology
Grob, T, Sanders, M A, Vonk, C M, Kavelaars, F G, Rijken, M, Hanekamp, D W, Gradowska, P L, Cloos, J, Fløisand, Y, van Marwijk Kooy, M, Manz, M G, Ossenkoppele, G J, Tick, L W, Havelange, V, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2023, ' Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 41, no. 4, pp. 756-765 . https://doi.org/10.1200/JCO.22.00715, https://doi.org/10.1200/JCO.22.00715
PURPOSE The applicability of FLT3-internal tandem duplications ( FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential ins
Autor:
Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja L. Gradowska, Bart J. Biemond, Dimitri A. Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin A. Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter J. M. Valk
Publikováno v:
Blood, 139(15), 2347-2354. AMER SOC HEMATOLOGY
Blood, 139(15), 2347-2354. American Society of Hematology
Grob, T, Al Hinai, A S A, Sanders, M A, Kavelaars, F G, Rijken, M, Gradowska, P L, Biemond, B J, Breems, D A, Maertens, J, van Marwijk Kooy, M, Pabst, T, de Weerdt, O, Ossenkoppele, G J, van de Loosdrecht, A A, Huls, G A, Cornelissen, J J, Beverloo, H B, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2022, ' Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome ', Blood, vol. 139, no. 15, pp. 2347-2354 . https://doi.org/10.1182/blood.2021014472
Blood, 139(15), 2347-2354. American Society of Hematology
Grob, T, Al Hinai, A S A, Sanders, M A, Kavelaars, F G, Rijken, M, Gradowska, P L, Biemond, B J, Breems, D A, Maertens, J, van Marwijk Kooy, M, Pabst, T, de Weerdt, O, Ossenkoppele, G J, van de Loosdrecht, A A, Huls, G A, Cornelissen, J J, Beverloo, H B, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2022, ' Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome ', Blood, vol. 139, no. 15, pp. 2347-2354 . https://doi.org/10.1182/blood.2021014472
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molec
Autor:
Tim, Grob, Mathijs A, Sanders, Christian M, Vonk, Franҫois G, Kavelaars, Melissa, Rijken, Diana W, Hanekamp, Patrycja L, Gradowska, Jacqueline, Cloos, Yngvar, Fløisand, Marinus, van Marwijk Kooy, Markus G, Manz, Gert J, Ossenkoppele, Lidwine W, Tick, Violaine, Havelange, Bob, Löwenberg, Mojca, Jongen-Lavrencic, Peter J M, Valk
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
The applicability ofIn 161 patients with de novoNGS-basedNGS-based detection of
Autor:
Annoek E. C. Broers, Cornelis N. de Jong, Katerina Bakunina, Mette D. Hazenberg, Marinus van Marwijk Kooy, Marco R. de Groot, Michel van Gelder, Jürgen Kuball, Bronno van der Holt, Ellen Meijer, Jan J. Cornelissen
Publikováno v:
Blood advances, 6(11), 3378-3385. The American Society of Hematology
HOVON Stem Cell Transplantation Working Group 2022, ' Posttransplant cyclophosphamide for prevention of graft-versus-host disease : results of the prospective randomized HOVON-96 trial ', Blood, vol. 6, no. 11, pp. 3378-3385 . https://doi.org/10.1182/bloodadvances.2021005847
Blood, 6(11), 3378-3385. American Society of Hematology
Blood Advances, 6(11), 3378-3385. AMER SOC HEMATOLOGY
Blood advances, 6(11), 3378-3385. American Society of Hematology
HOVON Stem Cell Transplantation Working Group 2022, ' Posttransplant cyclophosphamide for prevention of graft-versus-host disease : results of the prospective randomized HOVON-96 trial ', Blood, vol. 6, no. 11, pp. 3378-3385 . https://doi.org/10.1182/bloodadvances.2021005847
Blood, 6(11), 3378-3385. American Society of Hematology
Blood Advances, 6(11), 3378-3385. AMER SOC HEMATOLOGY
Blood advances, 6(11), 3378-3385. American Society of Hematology
Graft-versus-host disease (GVHD) is the most important complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). We performed a prospective randomized, multicenter, phase 3 trial to study whether posttransplant cyclophosphamide (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32996818b6d9a28257235f7969d0bfe9
https://cris.maastrichtuniversity.nl/en/publications/c7c230b3-1333-4c7e-aa88-350cf123e605
https://cris.maastrichtuniversity.nl/en/publications/c7c230b3-1333-4c7e-aa88-350cf123e605
Autor:
Coreline N. Burggraaff, Gregor Verhoef, Otto S. Hoekstra, Marie José Kersten, Lidwine W. Tick, Mels Hoogendoorn, Margreet Oosterveld, Daphne de Jong, Nicole C. H. P. van der Burg-de Graauw, Marinus van Marwijk Kooy, Matthijs H Silbermann, Aart Beeker, Marjolein van der Poel, Bart de Keizer, Eva de Jongh, Jeanette K. Doorduijn, Harry R. Koene, Thomas Stauffer Larsen, Memis Y Bilgin, Lara H Böhmer, Joost W. J. van Esser, Peter de Nully Brown, Marcel Nijland, Maria B.L. Leijs, J.F.M. Pruijt, Anne I.J. Arens, Josée M Zijlstra-Baalbergen, Pieternella J. Lugtenburg, Kon-Siong G. Jie, Rolf E. Brouwer, King H. Lam, Rob Fijnheer, Bronno van der Holt, Francesco d'Amore
Publikováno v:
Journal of Clinical Oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
Journal of Clinical Oncology, 38(29). American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma : A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of clinical oncology, 38(29), 3377-3387. American Society of Clinical Oncology
Lugtenburg, P J, De Nully Brown, P, Van der Holt, B, D'Amore, F A, Koene, H R, De Jongh, E, Fijnheer, R, Van Esser, J W, Bohmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, Van der Burg-De Graauw, N C, Oosterveld, M, Jie, K S G, Larsen, T S, Van der Poel, M W, Leijs, M B, Silbermann, M H, Van Marwijk Kooy, M, Beeker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, De Keizer, B, Arens, A I, De Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-chop with early rituximab intensification for diffuse large b-cell lymphoma : A randomized phase iii trial of the hovon and the nordic lymphoma group (hovon-84) ', Journal of Clinical Oncology, vol. 38, no. 29, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418
Journal of Clinical Oncology, 38, 29, pp. 3377-3387
Journal of Clinical Oncology, 38(29), 3377-3387. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 38(29):38, 3377-3387. American Society of Clinical Oncology
Journal of Clinical Oncology, 38, 3377-3387
Lugtenburg, P J, de Nully Brown, P, van der Holt, B, D'Amore, F A, Koene, H R, de Jongh, E, Fijnheer, R, van Esser, J W, Böhmer, L H, Pruijt, J F, Verhoef, G E, Hoogendoorn, M, Bilgin, M Y, Nijland, M, van der Burg-de Graauw, N C, Oosterveld, M, Jie, K-S G, Larsen, T S, van der Poel, M W, Leijs, M B, Silbermann, M H, van Marwijk Kooy, M, Beker, A, Kersten, M J, Doorduijn, J K, Tick, L W, Brouwer, R E, Lam, K H, Burggraaff, C N, de Keizer, B, Arens, A I, de Jong, D, Hoekstra, O S & Zijlstra-Baalbergen, J M 2020, ' Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84) ', Journal of Clinical Oncology, vol. 38, no. 29, 38, pp. 3377-3387 . https://doi.org/10.1200/JCO.19.03418, https://doi.org/DOI: 10.1200/JCO.19.03418
PURPOSE Immunochemotherapy with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) has become standard of care for patients with diffuse large B-cell lymphoma (DLBCL). This randomized trial assessed whether rituximab i
Autor:
Michele Cavo, Francesca Gay, Meral Beksac, Lucia Pantani, Maria Teresa Petrucci, Meletios A Dimopoulos, Luca Dozza, Bronno van der Holt, Sonja Zweegman, Stefania Oliva, Vincent H J van der Velden, Elena Zamagni, Giuseppe A Palumbo, Francesca Patriarca, Vittorio Montefusco, Monica Galli, Vladimir Maisnar, Barbara Gamberi, Markus Hansson, Angelo Belotti, Ludek Pour, Paula Ypma, Mariella Grasso, Alexsandra Croockewit, Stelvio Ballanti, Massimo Offidani, Iolanda D Vincelli, Renato Zambello, Anna Marina Liberati, Niels Frost Andersen, Annemiek Broijl, Rossella Troia, Anna Pascarella, Giulia Benevolo, Mark-David Levin, Gerard Bos, Heinz Ludwig, Sara Aquino, Anna Maria Morelli, Ka Lung Wu, Rinske Boersma, Roman Hajek, Marc Durian, Peter A von dem Borne, Tommaso Caravita di Toritto, Thilo Zander, Christoph Driessen, Giorgina Specchia, Anders Waage, Peter Gimsing, Ulf-Henrik Mellqvist, Marinus van Marwijk Kooy, Monique Minnema, Caroline Mandigers, Anna Maria Cafro, Angelo Palmas, Susanna Carvalho, Andrew Spencer, Mario Boccadoro, Pieter Sonneveld
Publikováno v:
Lancet Haematology, 7, 6, pp. E456-E468
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, von dem Borne, P A, Caravita di Toritto, T, Driessen, C, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U H, van Marwijk Kooy, M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. e456-e468 . https://doi.org/10.1016/S2352-3026(20)30099-5
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M-D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, Borne, P A V D, di Toritto, T C, Zander, T, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U-H, Kooy, M V M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. E456-E468 . https://doi.org/10.1016/S2352-3026(20)30099-5
The Lancet Haematology, 7(6), e456-e468. Lancet Publishing Group
The Lancet Haematology, 7(6), E456-E468. ELSEVIER SCI LTD
The Lancet Haematology, 7(6), E456-E468. Lancet Publishing Group
Lancet Haematology, 7, E456-E468
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, von dem Borne, P A, Caravita di Toritto, T, Driessen, C, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U H, van Marwijk Kooy, M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. e456-e468 . https://doi.org/10.1016/S2352-3026(20)30099-5
Cavo, M, Gay, F, Beksac, M, Pantani, L, Petrucci, M T, Dimopoulos, M A, Dozza, L, van der Holt, B, Zweegman, S, Oliva, S, van der Velden, V H J, Zamagni, E, Palumbo, G A, Patriarca, F, Montefusco, V, Galli, M, Maisnar, V, Gamberi, B, Hansson, M, Belotti, A, Pour, L, Ypma, P, Grasso, M, Croockewit, A, Ballanti, S, Offidani, M, Vincelli, I D, Zambello, R, Liberati, A M, Andersen, N F, Broijl, A, Troia, R, Pascarella, A, Benevolo, G, Levin, M-D, Bos, G, Ludwig, H, Aquino, S, Morelli, A M, Wu, K L, Boersma, R, Hajek, R, Durian, M, Borne, P A V D, di Toritto, T C, Zander, T, Specchia, G, Waage, A, Gimsing, P, Mellqvist, U-H, Kooy, M V M, Minnema, M, Mandigers, C, Cafro, A M, Palmas, A, Carvalho, S, Spencer, A, Boccadoro, M & Sonneveld, P 2020, ' Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95) : a multicentre, randomised, open-label, phase 3 study ', The Lancet Haematology, vol. 7, no. 6, pp. E456-E468 . https://doi.org/10.1016/S2352-3026(20)30099-5
The Lancet Haematology, 7(6), e456-e468. Lancet Publishing Group
The Lancet Haematology, 7(6), E456-E468. ELSEVIER SCI LTD
The Lancet Haematology, 7(6), E456-E468. Lancet Publishing Group
Lancet Haematology, 7, E456-E468
Background The emergence of highly active novel agents has led some to question the role of autologous haematopoietic stem-cell transplantation (HSCT) and subsequent consolidation therapy in newly diagnosed multiple myeloma. We therefore compared aut
Autor:
Christian Vonk, Tim Grob, Mathijs Sanders, François Kavelaars, Melissa Rijken, Diana Hanekamp, Patrycja Gradowska, Jaqueline Cloos, Yngvar Fl⊘isand, Marinus van Marwijk Kooy, Markus Manz, Gert Ossenkoppele, Lidwine Tick, Marie-Christiane Vekemans, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter Valk
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:S131